Single-cell and spatial transcriptomics to analyze radiation therapy-induced tumor microenvironment reshaping in HPV- cervical cancer.

Authors

null

Yan Zhang

Hong Kong University of Shenzhen Hospital, Shenzhen, China

Yan Zhang , Zhiyuan Xu , Bin Ye , Danyang Zheng , Caining Zhao , Wanli Xu , Lingyu MA , Zhibing Liang , Xiangyu Xiao , Li Yang , Hao Yu , Feng-Ming Spring Kong

Organizations

Hong Kong University of Shenzhen Hospital, Shenzhen, China, Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China, The University of Hong Kong, Hong Kong, China, University of Hong Kong, Hong Kong, China, Department of Clinical Oncology,The University of Hong Kong-Shenzhen Hospital, Shenzhen, China, University of Hong Kong - Shenzhen Hospital, Shenzhen, China, Hong Kong University Shenzhen Hospital, Shenzhen, China, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China

Research Funding

Institutional Funding
Shenzhen Science and Technology Program No.KQTD20180411185028798, 2021A1515110684

Background: Radiotherapy (RT) is the most widely used conventional first-line treatment in cervical cancer (CC). However, the treatment response rate was only 10%-40%, and even lower in HPV- negative CC (HPV- CC). So far, previous knowledge of radiotherapy on tumor and tumor immune microenvironment (TME) remodeling is still insufficient. In this study, we aimed to comprehensively understand the dynamic change of tumor and TME of HPV- CC at the single-cell level. Methods: The single-cell and spatial transcriptome sequencing (STRNAseq) were used to analyze the TME of newly diagnosed HPV- CC tumor tissues, including pre-radiotherapy and 3 weeks after radiotherapy. Tissue samples were split into two parts, the freshly lysed single-cell suspension for 10X single-cell sequencing, and another part that was immediately processed into frozen and embedded for STRNAseq. Cell clustering, annotation and Single-cell sequencing and spatial transcriptome integration were analyzed by Seurat 4.0. The CNV of epithelial cells (ECs) was estimated by InferCNV. Results: A total of 14000 cells were obtained from paired HPV-CC patient samples (pre-RT and 3 weeks after RT) and clustered into 21 cell subsets. Six EC subsets, four fibroblast subsets, three macrophage subsets, two T cell subsets, two B cell subsets, one mast cell cluster, and an endothelial cell cluster were discovered. CNV analysis revealed that all ECs were malignantly proliferating tumor cells. Tumor cells accounted for 90% of the total tumor tissue prior to RT, but only less than 1% of tumor cells remain after RT. Fibroblasts and myeloid cells, which make up 60% of tumor tissue, increase significantly after radiotherapy, with myeloid cells accounting for nearly 50% of the total. Furthermore, we found a population of cells in the Post-RT sample that were both highly expressed CD14 and CD68 (macrophage biomarkers) and highly expressed COL1A2 (fibroblast biomarker). Differential analysis showed that this group of cells was down-regulated in Focal adhesion and ECM-receptor interaction pathways, while up-regulated in cytokine secretion and phagosome pathways, indicating that this group of cells might remodel the intercellular matrix and interacted with other cells to regulate the immune microenvironment. Integrating single-cell and spatial transcriptome data, fibroblasts and myeloid cells formed a tight co-distribution in tissues after radiotherapy, implying that their interaction is critical for the formation of the tumor immune microenvironment. Conclusions: This study comprehensively analyzed the dynamic change of tumor and TME of HPV- CC treated with RT at the single-cell transcriptional scale. After radiotherapy, fibroblasts and myeloid cells significantly increased and were highly heterogeneous, and the interaction between them is critical in forming a tumor ecosystem for radiotherapy.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Cervical Cancer

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e17528)

DOI

10.1200/JCO.2023.41.16_suppl.e17528

Abstract #

e17528

Abstract Disclosures